(SKIN) Beauty Health - Overview
Stock: HydraFacial, Syndeo, Consumables, SkinStylus, Keravive
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 104% |
| Relative Tail Risk | -17.6% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.24 |
| Alpha | -43.48 |
| Character TTM | |
|---|---|
| Beta | 1.636 |
| Beta Downside | 2.265 |
| Drawdowns 3y | |
|---|---|
| Max DD | 94.01% |
| CAGR/Max DD | -0.56 |
Description: SKIN Beauty Health January 01, 2026
The Beauty Health Company (NASDAQ: SKIN) designs, develops, manufactures, markets, and sells aesthetic technologies and consumer-focused skin-care products across the Americas, APAC, Europe, the Middle East, and Africa. Its flagship HydraFacial system combines cleansing, extraction, and hydration using proprietary serums, while ancillary offerings include Syndeo personalized delivery devices, single-use consumables, the SkinStylus microneedling system for scar and acne treatment, and Keravive scalp-health solutions. The firm also runs the MyBeautyHealth mobile app, which rewards users with loyalty points, logs skin concerns, and connects them to certified providers.
In its most recent fiscal year, SKIN reported revenue of roughly $1.2 billion, a 20 % year-over-year increase driven by expanding provider networks-now exceeding 10,000 locations-and strong demand for non-invasive aesthetic procedures, a segment that is growing at an estimated 8 % compound annual rate globally. The companys gross margin remains above 70 %, reflecting the high-value, consumable-heavy nature of its business model, while operating cash flow has consistently covered capital expenditures, underscoring a solid financial foundation amid rising consumer discretionary spending on personal care.
For a deeper quantitative dive, the ValueRay platform offers granular financial metrics and peer comparisons that can help validate the outlook.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: -11.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 9.46 > 1.0 |
| NWC/Revenue: 81.63% < 20% (prev 118.3%; Δ -36.63% < -1%) |
| CFO/TA 0.08 > 3% & CFO 38.8m > Net Income -11.7m |
| Net Debt (159.6m) to EBITDA (29.1m): 5.48 < 3 |
| Current Ratio: 4.98 > 1.5 & < 3 |
| Outstanding Shares: last quarter (126.9m) vs 12m ago 2.28% < -2% |
| Gross Margin: 64.81% > 18% (prev 0.51%; Δ 6430 % > 0.5%) |
| Asset Turnover: 50.19% > 50% (prev 49.69%; Δ 0.49% > 0%) |
| Interest Coverage Ratio: 0.17 > 6 (EBITDA TTM 29.1m / Interest Expense TTM 15.4m) |
Altman Z'' -1.28
| A: 0.49 (Total Current Assets 308.4m - Total Current Liabilities 61.9m) / Total Assets 503.6m |
| B: -1.01 (Retained Earnings -509.4m / Total Assets 503.6m) |
| C: 0.00 (EBIT TTM 2.57m / Avg Total Assets 601.6m) |
| D: -1.17 (Book Value of Equity -511.1m / Total Liabilities 438.0m) |
| Altman-Z'' Score: -1.28 = CCC |
Beneish M -3.42
| DSRI: 0.80 (Receivables 25.4m/36.7m, Revenue 301.9m/347.6m) |
| GMI: 0.78 (GM 64.81% / 50.53%) |
| AQI: 1.29 (AQ_t 0.35 / AQ_t-1 0.27) |
| SGI: 0.87 (Revenue 301.9m / 347.6m) |
| TATA: -0.10 (NI -11.7m - CFO 38.8m) / TA 503.6m) |
| Beneish M-Score: -3.42 (Cap -4..+1) = AA |
What is the price of SKIN shares?
Over the past week, the price has changed by -14.67%, over one month by -12.93%, over three months by -0.78% and over the past year by -20.99%.
Is SKIN a buy, sell or hold?
- StrongBuy: 0
- Buy: 0
- Hold: 7
- Sell: 2
- StrongSell: 0
What are the forecasts/targets for the SKIN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 2 | 53.1% |
| Analysts Target Price | 2 | 53.1% |
| ValueRay Target Price | 0.8 | -39.1% |
SKIN Fundamental Data Overview February 04, 2026
P/S = 0.6335
P/B = 2.9322
P/EG = 0.9535
Revenue TTM = 301.9m USD
EBIT TTM = 2.57m USD
EBITDA TTM = 29.1m USD
Long Term Debt = 363.4m USD (from longTermDebt, last quarter)
Short Term Debt = 5.04m USD (from shortTermDebt, last quarter)
Debt = 379.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 159.6m USD (from netDebt column, last quarter)
Enterprise Value = 350.8m USD (191.3m + Debt 379.0m - CCE 219.4m)
Interest Coverage Ratio = 0.17 (Ebit TTM 2.57m / Interest Expense TTM 15.4m)
EV/FCF = 9.26x (Enterprise Value 350.8m / FCF TTM 37.9m)
FCF Yield = 10.79% (FCF TTM 37.9m / Enterprise Value 350.8m)
FCF Margin = 12.54% (FCF TTM 37.9m / Revenue TTM 301.9m)
Net Margin = -3.89% (Net Income TTM -11.7m / Revenue TTM 301.9m)
Gross Margin = 64.81% ((Revenue TTM 301.9m - Cost of Revenue TTM 106.2m) / Revenue TTM)
Gross Margin QoQ = 64.59% (prev 62.81%)
Tobins Q-Ratio = 0.70 (Enterprise Value 350.8m / Total Assets 503.6m)
Interest Expense / Debt = 1.67% (Interest Expense 6.31m / Debt 379.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = 2.03m (EBIT 2.57m * (1 - 21.00%))
Current Ratio = 4.98 (Total Current Assets 308.4m / Total Current Liabilities 61.9m)
Debt / Equity = 5.77 (Debt 379.0m / totalStockholderEquity, last quarter 65.7m)
Debt / EBITDA = 5.48 (Net Debt 159.6m / EBITDA 29.1m)
Debt / FCF = 4.21 (Net Debt 159.6m / FCF TTM 37.9m)
Total Stockholder Equity = 59.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.95% (Net Income -11.7m / Total Assets 503.6m)
RoE = -19.78% (Net Income TTM -11.7m / Total Stockholder Equity 59.4m)
RoCE = 0.61% (EBIT 2.57m / Capital Employed (Equity 59.4m + L.T.Debt 363.4m))
RoIC = 0.39% (NOPAT 2.03m / Invested Capital 517.3m)
WACC = 4.88% (E(191.3m)/V(570.2m) * Re(11.94%) + D(379.0m)/V(570.2m) * Rd(1.67%) * (1-Tc(0.21)))
Discount Rate = 11.94% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.71%
[DCF Debug] Terminal Value 80.82% ; FCFF base≈37.9m ; Y1≈24.9m ; Y5≈11.3m
Fair Price DCF = 1.58 (EV 361.4m - Net Debt 159.6m = Equity 201.8m / Shares 127.5m; r=5.90% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: -52.48 | EPS CAGR: -25.66% | SUE: 0.56 | # QB: 0
Revenue Correlation: -40.61 | Revenue CAGR: -2.57% | SUE: 0.25 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.05 | Chg30d=-0.003 | Revisions Net=-1 | Analysts=6
EPS next Year (2026-12-31): EPS=0.15 | Chg30d=+0.000 | Revisions Net=+0 | Growth EPS=-6.2% | Growth Revenue=+4.4%